COMMUNIQUÉS West-GlobeNewswire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
25/10/2018
MENLO PARK, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its third quarter 2018 financial results and provide a corporate update on November 1 [...]
HTG Molecular Diagnostics to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on Thursday, November 8
25/10/2018
TUCSON, Ariz., Oct. 25, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it will [...]
MRI Interventions Congratulates Axovant on First Patient Dosing in New Gene Therapy Clinical Study for Patients with Parkinson’s Disease
25/10/2018
Initial Data Expected in First Half of 2019 IRVINE, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- MRI Interventions (OTCQB:MRIC) congratulates Axovant Sciences Ltd. on the dosing of its first patient in a clinical study of [...]
Candesant Biomedical Announces Positive Safety and Efficacy Data for Treatment of Hyperhidrosis
25/10/2018
Novel treatment offers hope for people who suffer from excessive sweating SAN FRANCISCO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Candesant Biomedical (“Candesant”), a company dedicated to alleviating the suffering of those [...]
IRIDEX to Participate in Upcoming Investor Conferences
25/10/2018
MOUNTAIN VIEW, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in upcoming investor conferences. IRIDEX’s management is scheduled to present [...]
Harvard Bioscience Reports Third Quarter 2018 Financial Results
25/10/2018
-Reports GAAP and adjusted non-GAAP revenue of $28.6 million and $28.7 million, respectively, an increase of 53% and 15%, respectively- HOLLISTON, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. ( [...]
RxBenefit Clarity™ Available Soon to Allscripts Users
25/10/2018
New Offering from CoverMyMeds and RelayHealth Pharmacy Solutions Will Provide Accurate Prescription Price Information, Prescribing Decision Support and Streamlined Medication Access CHICAGO, Oct. 25, 2018 (GLOBE [...]
Inspire Medical Systems, Inc. to Present at the Stifel 2018 Healthcare Conference
25/10/2018
MINNEAPOLIS, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive [...]
Merit Medical Reports Earnings for Third Quarter of 2018
25/10/2018
Q3 2018 worldwide revenue of $221.7 million ($223.1 million on a comparable, constant currency* basis), up 23.6% as reported (up 24.4% on a comparable, constant currency* basis) over Q3 2017 Q3 2018 core revenue* up 14. [...]
Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology
25/10/2018
DUET publication highlighted during Best of ASN Journals session at ASN Kidney Week 2018 SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Journal of the American [...]
Cerner Reports Third Quarter 2018 Results
25/10/2018
KANSAS CITY, Mo., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Cerner Corporation (Nasdaq: CERN) today announced results for the 2018 third quarter that ended September 29, 2018. Bookings in the third quarter of 2018 were $1.588 [...]
N.M. Judge Orders NMDOH to Designate Dispensary Locations
25/10/2018
State agency must designate Ultra Health’s outstanding and future stores per judge’s order BERNALILLO, N.M., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Chief Judge Louis P. McDonald of the Thirteenth Judicial District has [...]
Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
25/10/2018
-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ADVOCATE Phase III Pivotal Trial in ANCA-Associated Vasculitis -- -- Reveals Potential New Role for Chemokine Receptor 2 ( [...]
GUERBET : Revenue at September 30, 2018
25/10/2018
€614.3M at constant exchange rates, up 2.1% Villepinte, 25 October 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €581.4M for the [...]
GUERBET : Chiffre d'affaires au 30 septembre 2018
25/10/2018
614,3 M€ à taux de change constant (TCC) en progression de 2,1% Villepinte, le 25 octobre 2018 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, publie un [...]
Nova Leap Health Corp. Closes Second Tranche of Brokered and Non-Brokered Private Placements
25/10/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Oct. 25, 2018 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) ("Nova Leap" or “the Company”), a [...]
Undoing Aging 2019 Conference Seeks Abstracts for Poster Session
25/10/2018
MOUNTAIN VIEW, Calif. and BERLIN, Oct. 25, 2018 (GLOBE NEWSWIRE) -- The SENS Research Foundation and the Forever Healthy Foundation are seeking abstracts for the 2019 Undoing Aging Conference poster sessions. Undoing [...]
Certis Oncology Collaborates With Science Exchange to Offer On-Demand Access to its Orthotopic PDX Services
25/10/2018
SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Science Exchange, the leading marketplace for outsourced R&D, and Certis Oncology , a leading provider for preclinical mouse modeling and tumor banking services, [...]
Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia
25/10/2018
Valby, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Corporate Release Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia Lu AF35700 did not show statistical superiority versus [...]

Pages